Condition (MeSH)
Tertiary Lymphoid Structures
ClinicalTrials.gov lists 14 trials for Tertiary Lymphoid Structures or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
14 of the 14 trials are tagged with Tertiary Lymphoid Structures itself; the rest are tagged with a narrower condition beneath it.
When did Tertiary Lymphoid Structures trials start? (9)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2012 | 1 |
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Tertiary Lymphoid Structures trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 7 |
| Not applicable | 2 |
| Observational | 4 |
How many Tertiary Lymphoid Structures trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 2 |
| Active, not recruiting | 2 |
| Completed | 4 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which drugs are being tested for Tertiary Lymphoid Structures? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| TORIPALIMAB | 2 |
| AXITINIB | 2 |
| DURVALUMAB | 1 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Additional blood sample | 1 |
| Phase 2 : Regorafenib | 1 |
| Bintrafusp alfa/M7824 | 1 |
| Doxorubicine | 1 |
| Phase 2: low-dose Regorafenib | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Tertiary Lymphoid Structures? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. | Immunity | 2022 | Yes |
| Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. | Nature medicine | 2022 | Yes |
| Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. | Nature cancer | 2021 | Yes |
| BAFF Induces Tertiary Lymphoid Structures and Positions T Cells within the Glomeruli during Lupus Nephritis. | Journal of immunology (Baltimore, Md. : 1950) | 2017 | Yes |
| A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer. | JCI insight | 2024 | No |
Showing 5 of 8 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.